ICLR Fail-to-Deliver

ICON Public Limited Company (ICLR) operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry, with a market capitalization near $8.96B, listed on NASDAQ, employing roughly 41,250 people, carrying a beta of 1.23 to the broader market. ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. Led by Barry Balfe, public since 1998-05-15.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date
2026-04-22
Latest FTD Quantity
78
Latest Price
$115.18
30-Day Avg FTD
18.7K
30-Day Total FTD
559.6K

Showing 30 days of SEC fail-to-deliver data for ICON Public Limited Company.

Learn how fails-to-deliver is reported and how to read the data →

Frequently asked ICLR fail to deliver questions

What is the latest ICLR fail-to-deliver count?
As of Apr 22, 2026, ICON Public Limited Company (ICLR) fail-to-deliver quantity is 78 shares, with a 30-day average of 18.7K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
What is the FTD aggregate net balance?
FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
How do ICLR FTDs affect options pricing?
Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.